BlackRock, Inc. Reduces Stake in Lifecore Biomedical, Inc.

BlackRock, Inc. has filed a Schedule 13G/A amendment with the SEC, reporting a reduction in its stake in Lifecore Biomedical, Inc. As of September 30, 2025, BlackRock owns 1,834,319 shares, representing 4.9% of the company's common stock. This marks a significant decrease from its previous holdings, with a reduction of 14,141,027 shares, or 88.52% of its prior stake. The filing indicates that BlackRock has sole voting power over 1,804,675 shares and sole dispositive power over all 1,834,319 shares. The filing also certifies that the shares were acquired and are held in the ordinary course of business, not for the purpose of influencing control of the issuer.